{'fraction_non_alphanumeric': 0.021037868162692847, 'fraction_numerical': 0.018934081346423562, 'mean_word_length': 5.177489177489178, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A profile on capmatinib in treating adult patients with metastatic NSCLC tumors with MET exon 14 skipping mutations

ABSTRACT Introduction : Clinical studies of MET-targeted treatments have so far failed to provide adequate outcomes. Capmatinib, a newly designed MET receptor inhibitor, has demonstrated considerable anticancer efficacy in patients with advanced NSCLC who have a MET exon 14 skipping mutation. Areas covered : This review offers a summary of the findings from capmatinib clinical studies in NSCLC patients with a MET exon 14 skipping mutation, as well as preclinical data and post-market reporting of capmatinib. Expert opinion : Capmatinib has a tolerable safety profile and preliminary evidence of effectiveness in patients with a MET exon 14 skipping mutation, according to data from a phase 1 clinical study. The GEOMETRY mono-1 phase 2 study revealed objective response rates of 68% and 41%, and median OS of 20.8 and 13.6 months in treatment-naive and pretreated MET exon 14 skipping mutant patients, respectively. Furthermore, capmatinib penetrates the blood–brain barrier, and capmatinib activity in the brain was shown to be encouraging in the study. However, the effectiveness of immunotherapy for MET exon 14 skipping mutation remains debatable. To enhance therapy choices, researchers have begun to focus on the mechanisms of intrinsic and acquired resistance of the MET exon 14 skipping mutation.